INTRODUCTION
============

According to 2015 Korean cancer statistics \[[@b1-ac-2018-08-02-1]\], colorectal cancer (CRC) is the 2nd most common type of cancer, followed by stomach cancer, with 26,790 cases nationwide in 2015. The annual standardized incidence rate of CRC increased by 6.0% annually between 1999 and 2010 and then decreased from 2010 to 2015 by 6.1%. The age-standardized incidence rate in 2015 was 30.4/

100,000, making this the third most common cancer during this period. The age-standardized mortality rate for CRCs increased until 2004 by 5.5% annually and then began to decrease between 2004 and 2015 by 1.3% annually. The age-standardized rate of death from CRC per 100,000 in 2016 was 16.5, with CRC serving as the 3rd leading cause of death across all cancers in that year. Not only have the incidence and the mortality rates associated with these cancers changed over time, but so have the diagnosis and the treatment strategies for patients with CRCs, leading to significant improvements in the oncologic outcomes in Korea \[[@b2-ac-2018-08-02-1]-[@b4-ac-2018-08-02-1]\].

While others (e.g., Park et al. \[[@b5-ac-2018-08-02-1]\]) have previously reported the characteristics and the survival rates for patients with CRCs from 1993 to 2010, current rates should also be assessed as they have changed \[[@b1-ac-2018-08-02-1]\]. In addition, previous work did not investigate changes in frequency or survival rates per SEER (Surveillance, Epidemiology, and End Results) summary stage as the Korea Central Cancer Registry (KCCR) only began to report SEER summary stage data in 2006.

Since 1999, nationwide cancer incidence data have been recorded in the KCCR, which serves to collect information on cancer patients from registered hospitals. Additionally, the KCCR and regional cancer registries have directly surveyed information on previously unreported cancer patients by using a national insurance database. The KCCR is thought to include data from all cancer patients in Korea, making it an ideal tool for the analyses conducted here \[[@b1-ac-2018-08-02-1]\]. The purpose of this study was to investigate the characteristics of Korean patients with CRC, focusing on survival outcomes across tumor distribution, stage, and patient sex and age by using data from a nationwide cancer registry. Changes in survival rates were also assessed across discrete time periods or epochs.

METHODS
=======

We retrieved clinical data on 326,712 patients with CRC diagnosed between 1996 and 2015. Pathologically-identified adenocarcinomas of the colon and rectum were included in the present study. Patient age, sex, and clinical data (such as tumor distribution and stage) were retrieved from the Korea National Cancer Incidence Database and used for analyses. This study was exempted from approval and informed consent by the Institutional Review Board of Severance Hospital Yonsei University Health System.

Relative survival rates (RSRs) were calculated across predefined 5-year time periods: 1996--2000, 2001--2005, 2006--2010, 2006--2010, and 2011--2015. Trends in relative survival from CRC by diagnostic year were illustrated using the Kaplan-Meier method. Tumor location was classified according to the following categories: the right side of the colon (from the cecum, including the appendix, to the colon's hepatic flexure), transverse colon, left side of the colon (from the splenic flexure to the sigmoid colon), rectosigmoid, and the rectum. SEER stages (local, regional, and distant) were available for patients identified from 2006 to 2015. In brief, SEER local stage data included tumors confined to their origin organ (i.e., colon or rectum) without lymph-node metastasis. Regional disease included tumors with adjacent organ invasion or regional lymph-node metastasis. Distant disease included those with distant site metastasis. A comparison of SEER stages across TNM stages is shown in supplementary [Table 1](#t1-ac-2018-08-02-1){ref-type="table"}. The 5-year RSR was adjusted for the mortality expected among others of the same age and sex. The RSRs were calculated using the Ederer II method \[[@b6-ac-2018-08-02-1]\]. Log-rank tests were used to test for differences in survival rates.

Estimated survival rates were compared across tumor distribution, stage, patient's sex (male and female), and patient's age at diagnosis (≤39, 40--49, 50--59, 60--69, and ≥70 years). All statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA), and statistically significance was considered to be indicated by a P-value of less than 0.05.

RESULTS
=======

Distribution of CRC according to tumor site, stage, and patient's sex and age
-----------------------------------------------------------------------------

Korean CRC tumor distribution statistics have changed annually. The rate of colon cancer increased from 49.5% in 1996--2000 to 66.4% in 2011--2015. Right-sided colon cancers increased from 15.9% to 20.0%, transverse colon cancers from 4.1% to 4.9%, left-sided colon cancers from 22.9% to 31.9%, and rectosigmoid junction cancers from 6.6% to 9.6%. However, the total rate of rectal cancer decreased from 50.5% to 33.6% during the same period. This change was observed in both males and females. The proportion of right-sided colon cancers in females increased steeply and was higher than that among males (25.4% vs. 16.4%) between 2011 and 2015. The proportion of left-sided colon cancers in females had a similar trend from 1996 to 2015. The proportion of left-sided colon and rectal cancers in males was higher than in females between 2001 and 2015 ([Fig. 1](#f1-ac-2018-08-02-1){ref-type="fig"}).

In both time periods (2006--2010 and 2011--2015), a regional tumor stage designation was more common than a local stage designation. From 2011 to 2015, the proportion of all tumors with a regional stage designation across both sexes was 43.4%; 35.3% were local stage tumors, and 15.9% were distant stage tumors. This order was evident among both male and female patients when analyzed independently ([Fig. 2](#f2-ac-2018-08-02-1){ref-type="fig"}).

The incidence of CRC by age in both time periods decreased in the following order: ≥70, 60--69, 50--59, 40--49, and ≤39 years ([Fig. 3](#f3-ac-2018-08-02-1){ref-type="fig"}). In patients aged 50--59 and 60--69, the proportion of local stage tumors was higher than in the other age groups. Those aged 40--49 and ≥70 years had similar proportions of tumors distributed across SEER stages. Those aged less than 39 had the highest proportion of advanced stage tumors (regional, 47.1% and distant, 20.8%) ([Fig. 4](#f4-ac-2018-08-02-1){ref-type="fig"}). Those over 70 years of age had the highest proportion of right-sided colon cancers of all age groups (24.2% vs. 18.9% in those 60--69, 16.1% in those 50--59, 15.5% in those 40--49, and 18.6% in those ≤39 years), though the proportion of rectal cancers was lower in these patients than in those of a younger age (31.6% vs. 32.6% in those 60--69, 36.2% in those 50--59, 38.4% in those 40--49, and 34.9% in those ≤39 years) ([Fig. 5](#f5-ac-2018-08-02-1){ref-type="fig"}).

RSRs for CRCs by tumor site, stage, and patient's sex and age
-------------------------------------------------------------

The 5-year RSRs for patients with all CRCs and for those with right-sided colon, transverse colon, left-sided colon, rectosigmoid, and rectum cancers by time period are summarized in [Table 1](#t1-ac-2018-08-02-1){ref-type="table"}. Survival improved significantly across all tumor sites, with left-sided colon cancers having the most favorable outcomes across all time periods ([Fig. 6](#f6-ac-2018-08-02-1){ref-type="fig"}). In both the total cohort and among female patients, right-sided and transverse colon cancers had more favorable outcomes than did rectosigmoid and rectal cancers from 1996 to 2000. In contrast, from 2001 to 2015, rectosigmoid and rectal cancers had more favorable survival outcomes than did right-sided or transverse colon cancers. In male patients, survival rates for right-sided and transverse colon cancers were higher than they were for rectosigmoid or rectal cancers across all time periods. Females had worse survival rates across the entire assessed time period ([Table 1](#t1-ac-2018-08-02-1){ref-type="table"}).

Survival rates according to SEER stage were compared between the 2006--2010 and the 2011--2015 time periods. Survival with local or regional SEER stage tumors significantly increased from 2006--2010 to 2011--2015 (92.8% vs. 94.7%, P \< 0.0001 for local SEER stage; 78.8% vs. 81.6%, P \< 0.0001 for regional SEER stage) and did not differ for distant stage tumors (19.7% vs. 19.6%, P = 0.9859) ([Table 2](#t2-ac-2018-08-02-1){ref-type="table"}). Survival rates for patients with local stage tumors increased between the 2006--2010 and the 2011--2015 time periods by more than 90% while survival rates for those with regional stage CRC tumors increased annually, with survival rates for patients with regional stage colon cancer tumors increasing by more than 80% from 2011 to 2015. However, survival rates for patients with rectal cancers were 76.1% for the 2006--2010 time period and 78.9% for the 2011--2015 period. Survival rates for patients with distant stage colon cancer tumors on the left side of the colon increased from 21.8% in 2006--2010 to 23.3% in 2011--2015. Right-sided colon, transverse colon, rectosigmoid, and rectal cancer tumors with a distant stage classification were associated with decreased survival rates from 2006--2010 to 2011--2015. This was especially true for right-sided and transverse colon cancers of a distant stage, which had lower survival than left-sided colon, rectosigmoid, and rectal cancers ([Table 3](#t3-ac-2018-08-02-1){ref-type="table"}).

More favorable overall survival rates were found in certain age groups, with the survival rate decreasing in the following order in both the 2006--2010 and the 2011--2015 time periods: 50--59, 60--69, 40--49, ≤39, and ≥70 years. This order was the same for those with local stage tumors. Those aged 50--59 and 60--69 had the most favorable overall survival outcomes, with rates over 80% in the 2011--2015 time period (82.1% and 81.2%, respectively). Those above 70 years of age had the worst overall survival rate at 64.8% in 2011--2015. For patients with regional stage tumors, those aged 40--49 had more favorable survival outcomes than those aged 60--69. For patients with distant stage tumors, the most favorable survival outcome was found among those aged 40--49 ([Table 4](#t4-ac-2018-08-02-1){ref-type="table"}).

In patients with transverse colon, left-sided colon, rectosigmoid, and rectal cancers, those aged 50--59 had more favorable survival rates, with the order of survival by age group proceeding in the same order as it did for the overall cohort (listed above). Those younger than 39 had the best survival rates for right-sided colon cancers while those older than 40 had the highest survival rates for left-sided colon cancers ([Table 5](#t5-ac-2018-08-02-1){ref-type="table"}).

DISCUSSION
==========

Due to advancements in the treatment of patients with CRC and the extraordinary efforts made by Korean clinicians, a steady improvement of CRC survival rates in Korea and globally, as evidenced in the present study and others, has occurred across the last several decades. A recent study of global cancer survival rates, including individual data from 25,676,887 patients across 279 population-based registries in 67 countries from 1995 to 2009, included data on colon cancer, specifically, for 3,613,067 patients \[[@b7-ac-2018-08-02-1]\]. For patients diagnosed with colon cancer between 2005 and 2009, the age-standardized 5-year net survival rates were 50%--59% in many countries. Specifically in Korea, the 5-year survival rate was 42.5% between 1995 and 1999, though this increased to 60.4% between 2000 and 2004 and further to 66.0% between 2005 and 2009. These survival outcomes were better than those in the other countries assessed, including a survival rate of 64.7% in the United States and 64.4% in Japan. Rectal cancer data from this large study are also available for 1,413,861 patients. For patients diagnosed with rectal cancer between 2005 and 2009, the age-standardized 5-year net survival rates were 50%--59% in many countries. Survival rates were especially high in Korea, at 51.6% between 1995 and 1999, 60.8% between 2000 and 2004, and 65.9% between 2005 and 2009. As with colon cancer, these rectal cancer survival rates are better than the other assessed rates, including the rate in the United States (64.0%) or Japan (60.3%).

An anatomical rightward-shift in CRC incidence rates has also been reported in recent studies \[[@b8-ac-2018-08-02-1]-[@b12-ac-2018-08-02-1]\]. For example, the American Cancer Society reported a higher proportion of right-sided colon cancers (41%) than left-sided ones (22%) in the United States from 2009 to 2013. However, a striking variation in this distribution is seen by patient's sex and age at diagnosis. In the United States, the likelihood of a proximal tumor location is greater in women than in men and increases with age. For example, 57% of CRCs in women aged 80 years and older occur in the proximal colon versus just 26% in men younger than 50 years of age. Among both men and women younger than 50, of all the regions assessed, CRC tumors are most commonly diagnosed in the rectum (41% and 36%, respectively) \[[@b12-ac-2018-08-02-1]\]. In the present study, females and those older than 70 years of age had a higher proportion of right-sided colon cancers than did males and those in younger age groups. Otherwise, men and those aged below 60 had the highest proportion of rectal cancers.

Data revealed in the present study compare well to those reported previously. A steep increase in right-sided colon cancers in females was observed in this study. Similarly, in Europe, the proportion of CRCs presenting in the proximal colon has increased significantly from 27% to 32% in men and from 35% to 41% in women between the period from 1994 to 1997 and that from 2010 to 2012 \[[@b13-ac-2018-08-02-1]\]. The increase in distal colon cancers, followed by proximal colon cancers, reported by previous studies \[[@b9-ac-2018-08-02-1]-[@b11-ac-2018-08-02-1]\] was also observed in the present study. Additionally, a steady decrease in the incidence of rectal cancers reported in the present study has also been reported by others. Overall, the Japanese and the Israeli populations have been found to have the highest incidence rates for cancers in the proximal and distal colon while those in Israel and China have the lowest incidence rates of rectal cancers \[[@b3-ac-2018-08-02-1], [@b14-ac-2018-08-02-1]\].

An increase in the survival rates across time in all tumor categories studied here was observed in the present study. Typically, left-sided colon cancers had more favorable associated outcomes than did right-sided colon cancers in all time periods assessed here. Notably, recent studies have also reported a worse prognosis associated with right-side colon cancers \[[@b8-ac-2018-08-02-1]-[@b11-ac-2018-08-02-1]\], though no clear explanation has been given for this trend. Other tumor differences may be less variable in terms of associated mortality. For instance, Weiss et al. \[[@b15-ac-2018-08-02-1]\] reported no difference between the 5-year mortality rates associated with proximal and distal colon cancer tumors. They found that while proximal colon tumors had a better prognosis in stage II, they had a worse prognosis in stage III. They suggested that this finding might be due to differences in tumor biology, including microsatellite instability (MSI). MSI-high cancers are more frequently found in stage II proximal colon cancers and are associated with a more favorable prognosis.

Primary tumors arising from the left and the right sides of the colon also differ in terms of their distinct chromosomal and molecular characteristics. High MSI, CIMP, and MLH1 methylation levels are more likely to occur in right-sided than left-sided colon cancers \[[@b16-ac-2018-08-02-1]\]. In contrast, higher chromosomal instability is observed in left-sided colon cancers \[[@b17-ac-2018-08-02-1]\]. Frequently, genetic mutations and distributions of CM5 subtypes differ between right- and left-sided CRCs (e.g., *KRAS, BRAF, TGFbR2*, and *PI3KCA* mutations are more common in right-sided CRCs while *TP53, APC*, and *KRAS* mutations are more common in left-sided CRCs) \[[@b18-ac-2018-08-02-1]\]. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 1 expressions have also been reported to be significantly higher in left-sided than in right-sided CRCs \[[@b19-ac-2018-08-02-1]\].

A difference in molecular pathways may underlie differences in the presentation and the clinical outcomes associated with CRCs of differing locations, though the reasons for these differences remain mostly unknown. Differential distributions of genomic CRC subtypes and other biologic features between left- and right-sided CRCs may contribute to an inferior prognosis with advanced stage right-sided CRC and to an inferior prognosis with anti-EGFR therapy in right-sided CRC. In the present study, right-sided and transverse colon cancers were also associated with a poorer prognosis than were left-sided, rectosigmoid, and rectal cancers between 2001 and 2015. Tumors in the local and the regional stages were further associated with lower survival rates when they were right-sided in transverse and rectosigmoid colon cancers, but not in rectal cancer, than when they were left-sided. Right-sided and transverse colon cancers were associated with poorer survival rates than were left-sided, rectosigmoid, and rectal cancers of a distant stage.

Above all, the most promising outcome from the present study is the improvement of survival rates for patients with rectal cancers over time. From 1996--2000, rectal cancers were associated with worse survival rates than were right-sided colon cancers (56.9% vs. 63.1%, respectively). After 2001, rectal cancer was associated with better survival rates than were right-sided colon cancers (74.6% vs. 73.0%, respectively, from 2011--2015). This increased survival may be due to improvements in and standardizations of surgical techniques, including the total mesorectal excision and the combined radical resection, for the treatment of local, advanced rectal cancers \[[@b20-ac-2018-08-02-1], [@b21-ac-2018-08-02-1]\]. Furthermore, advances in pre- and postoperative adjuvant treatments, including chemotherapy and radiotherapy, have increased radical resection rates and decreased local recurrence rates in patients with CRC \[[@b22-ac-2018-08-02-1]\].

The SEER staging system used here differs slightly from the TNM staging system. Localized colon cancer corresponding to stage I or IIA requires no adjuvant chemotherapy. Regional CRCs corresponding to stages IIB or IIC and stage III require adjuvant chemotherapy for colon cancer and chemoradiotherapy for rectal cancer. Local stage cancers have a 5-year survival rate that is extremely high (94.7% between 2011 and 2015, increased from 92.8% between 2006 and 2010). Regional stage cancers have also experienced increased survival rates recently (from 78.8% between 2006 and 2010 to 81.6% between 2011 and 2015). Despite advances in chemotherapeutics over the past few decades, survival outcomes for distant stage CRCs have not improved between the 2006--2010 and the 2011--2015 epochs (2-year survival rate: 40.2% vs. 40.7%, 5-year survival rate: 19.7% vs. 19.6%, respectively). Improved surgical techniques and advanced instruments and systems may, however, further increase these survival rates and the qualities of life for patients with local and regional stage CRCs.

Chemotherapy plays an important role as an adjuvant treatment for patients with regional stage CRCs and is a first-line treatment for patients with distant stage CRCs. However, target agents, such as bevacizumab and cetuximab, have demonstrated no significant improvements in survival outcomes for those with distant stage CRCs. Greater efforts must be made and multidisciplinary approaches that combine surgery, chemotherapy, and radiotherapy must be taken if the survival outcomes for patients with distant stage CRCs are to be improved. Furthermore, early CRC screening and increased rates of examination should be encouraged in public health domains to improve patient prognoses.

Public health issues surrounding cancer screening and diagnoses often interact with the patient's sex and other characteristics. For example, males may be exposed to more colon cancer risk factors, including cigarette smoke and alcohol \[[@b23-ac-2018-08-02-1], [@b24-ac-2018-08-02-1]\]. Meanwhile, women are more likely to develop MSI-high proximal colon cancers \[[@b25-ac-2018-08-02-1]\]. This may have led to improved prognoses in females, as has been reported previously \[[@b26-ac-2018-08-02-1]\]. However, the present study reports a contradictory result---worse survival rates in females. This difference was most prominent among those over 70, a finding which may be further attributed to poorer socioeconomic associations among elderly women \[[@b27-ac-2018-08-02-1]\]. For example, elderly women tend to pursue and receive less aggressive therapy for advanced diseases. Additionally, these patients may be presented with fewer opportunities for regular health checks and disease screening.

CRC prognoses among younger patients remain a controversial issue. While some studies have reported that younger patients, including those with later stage cancers and exhibiting more proximal, aggressive tumor histology \[[@b28-ac-2018-08-02-1]\], face a worse prognosis, others have reported no worse prognosis among the young \[[@b29-ac-2018-08-02-1]\]. In the present study, middle aged (40--69 years) patients had the most favorable survival outcomes, followed by the youngest (≤39 years) and the oldest (≥70 years) patients across all tumor stage categories. Those younger than 39 typically had the highest portion of advanced stage cancers among all age groups, an association that may have contributed to poorer survival outcomes in this group. The youngest patients had survival rates for right-sided and transverse colon cancers comparable to those for middle-aged patients (40--69 years), though these rates differed for left-sided, rectosigmoid, and rectal cancers, for which younger patients had poorer survival rates. Patients over 70 years of age had poorer survival rates than younger patients, regardless of SEER stage and tumor location.

The age-related associations revealed here may be attributed to several factors. In the present study, those older than 70 had the highest proportion of right-sided colon cancers and the lowest proportion of local stage tumors. Furthermore, elderly patients may receive less aggressive therapy, have a greater comorbidity burden, and have poorer performance scores. Treatment parity may underlie these differences. For instance, studies have demonstrated that, given the same level of treatment, elderly patients have survival rates comparable to those of the younger comparators \[[@b30-ac-2018-08-02-1]\]. Considering an ever-expanding elderly population, future studies should examine this phenomenon in more detail to identify its causes and, thus, improve CRC treatment outcomes.

In summary, the findings presented here reveal that survival rates among patients with CRCs, and especially those with rectal cancer, have improved dramatically in recent years. Survival rates among patients with a local or regional SEER CRC tumor stage have also improved. Our study findings may lead to further macroscopic insights into the nature of CRC and improved prognoses for patients with these cancers in South Korea.
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###### 

Trends in 5-year relative survival by tumor distribution according to time period

  Sex and tumor sites              1996-2000       2001-2005       2006-2010        2011-2015        Absolute change (%)[^a^](#tfn1-ac-2018-08-02-1){ref-type="table-fn"}
  -------------------------------- --------------- --------------- ---------------- ---------------- ----------------------------------------------------------------------
  Both sexes                                                                                         
   Colon & rectum (C18-C20)        38,739 (58.7)   66,935 (66.2)   101,579 (72.6)   119,459 (75.0)   16.3
   Right side colon (C18.0-18.3)   5,577 (63.1)    10,519 (65.6)   17,323 (71.0)    22,664 (73.0)    9.9
   Transverse colon (C18.4)        1,430 (62.1)    2,518 (65.4)    4,261 (71.4)     5,505 (74.6)     12.5
   Left side colon (C18.5-18.7)    8,013 (64.0)    16,099 (70.0)   29,487 (75.9)    36,155 (78.3)    14.3
   Rectosigmoid (C19.9)            2,318 (56.9)    4,067 (67.1)    7,142 (74.4)     10,906 (75.1)    18.2
   Rectum (C20.9)                  17,653 (57.7)   28,290 (66.7)   36,748 (72.3)    38,030 (74.6)    16.9
  Men                                                                                                
   Colon & rectum (C18-C20)        21,269 (59.7)   38,266 (68.0)   60,504 (74.5)    71,522 (76.8)    17.1
   Right side colon (C18.0-18.3)   2,797 (66.0)    5,229 (69.2)    8,838 (74.9)     11,079 (76.2)    10.2
   Transverse colon (C18.4)        758 (66.1)      1,381 (68.4)    2,444 (74.7)     3,141 (78.8)     12.7
   Left side colon (C18.5-18.7)    4,566 (66.4)    9,567 (72.1)    18,151 (77.7)    22,550 (79.4)    13.0
   Rectosigmoid (C19.9)            1,322 (57.2)    2,416 (68.5)    4,404 (75.3)     6,825 (75.8)     18.6
   Rectum (C20.9)                  9,878 (56.9)    16,628 (66.7)   22,649 (72.7)    24,158 (75.4)    18.5
  Women                                                                                              
   Colon & rectum (C18-C20)        17,470 (57.6)   28,669 (63.8)   41,075 (69.8)    47,937 (72.3)    14.7
   Right side colon (C18.0-18.3)   2,780 (60.1)    5,290 (62.0)    8,485 (67.0)     11,585 (69.9)    9.8
   Transverse colon (C18.4)        672 (57.7)      1,137 (61.8)    1,817 (67.0)     2,364 (68.9)     11.2
   Left side colon (C18.5-18.7)    3,447 (60.9)    6,532 (66.9)    11,336 (73.2)    13,605 (76.5)    15.6
   Rectosigmoid (C19.9)            996 (56.4)      1,651 (65.2)    2,738 (73.0)     4,081 (73.9)     17.5
   Rectum (C20.9)                  7,775 (58.6)    11,662 (66.7)   14,099 (71.5)    13,872 (73.1)    14.5

Values are presented number (%).

Percentage change in 5-year relative survival from 1996 to 2000 and 2011 to 2015.

###### 

Five-year relative survival by SEER stage between 2006--2010 and 2011--2015

  SEER stage   Both sexes       Change[^a^](#tfn2-ac-2018-08-02-1){ref-type="table-fn"}   Male   Change[^a^](#tfn2-ac-2018-08-02-1){ref-type="table-fn"}   Female          Change[^a^](#tfn2-ac-2018-08-02-1){ref-type="table-fn"}                                   
  ------------ ---------------- --------------------------------------------------------- ------ --------------------------------------------------------- --------------- --------------------------------------------------------- --------------- --------------- ------
  Overall      101,579 (72.6)   119,459 (75.0)                                            2.4    60,504 (74.5)                                             71,522 (76.8)   2.3                                                       41,075 (69.8)   47,937 (72.3)   2.5
  Local        33,734 (92.8)    42,142 (94.7)                                             1.9    20,904 (94.1)                                             26,319 (95.9)   1.8                                                       12,830 (90.6)   15,823 (92.7)   2.1
  Regional     41,618 (78.8)    51,901 (81.6)                                             2.8    24,479 (80.0)                                             30,602 (82.4)   2.4                                                       17,139 (77.2)   21,299 (80.5)   3.3
  Distant      15,557 (19.7)    18,943 (19.6)                                             -0.1   8,954 (20.0)                                              10,976 (20.5)   0.5                                                       6,603 (19.3)    7,967 (18.3)    -1
  Unknown      10,670 (61.3)    6,473 (54.0)                                              -7.3   6,167 (65.0)                                              3,625 (58.8)    -6.2                                                      4,503 (56.3)    2,848 (47.9)    -8.4

Values are presented number (%).

SEER, Surveillance, Epidemiology, and End Results.

Percentage change in 5-year relative survival from 1996 to 2000 and 2011 to 2015.

###### 

Five-year relative survival of all patients by tumor distribution and SEER stage between 2006--2010 and 2011--2015

  SEER stage   Right side colon (C18.0--C18.3)   Transverse colon (C18.4)   Left side colon (C18.5--18.7)   Rectosigmoid (C19.9)   Rectum (C20.9)                                                                  
  ------------ --------------------------------- -------------------------- ------------------------------- ---------------------- ---------------- --------------- -------------- --------------- --------------- ---------------
  Overall      17,323 (71.0)                     22,664 (730)               4,261 (71.4)                    5,505 (74.6)           29,487 (75.9)    36,155 (78.3)   7,142 (74.4)   10,906 (75.1)   36,748 (72.3)   38,030 (74.6)
  Local        4,975 (93.8)                      7,027 (95.0)               1,308 (93.8)                    1,854 (95.4)           10,025 (95.0)    13,255 (96.5)   2,074 (93.5)   3,169 (96.0)    12,882 (91.0)   13,962 (93.4)
  Regional     8,036 (77.8)                      10,837 (80.5)              1,914 (78.0)                    2,604 (80.8)           12,141 (83.5)    15,427 (85.7)   3,323 (81.6)   5,523 (83.5)    14,963 (76.1)   16,381 (78.9)
  Distant      2,924 (18.0)                      3,951 (17.8)               675 (16.7)                      819 (15.1)             4,831 (21.8)     5,942 (23.3)    1,073 (21.3)   1,835 (19.5)    4,907 (20.6)    5,356 (19.6)
  Unknown      1,388 (62.0)                      849 (49.7)                 364 (57.2)                      228 (49.5)             2,490 (67.5)     1,531 (58.6)    672 (64.2)     379 (45.3)      3,996 (60.4)    2,331 (55.6)

Values are presented number (%).

SEER, Surveillance, Epidemiology, and End Results.

###### 

Five-year relative survival of all patients by age group and SEER stage between 2006--2010 and 2011--2015

  SEER stage   Year        ≤39 yr   40-49 yr            50-59 yr   60-69 yr           ≥70 yr                                                           
  ------------ ----------- -------- ------------------- ---------- ------------------ -------- ------------------ -------- ------------------ -------- ------------------
  Overall      2006-2010   3,161    73.6 (72.1-75.2)    10,471     77.4 (76.6-78.2)   23,113   79.9 (79.4-80.5)   30,885   77.6 (77.0-78.1)   33,949   60.8 (60.1-61.4)
               2011-2015   2,848    75.6 (73.5-77.5)    10,037     79.4 (78.3-80.3)   27,474   82.1 (81.5-82.7)   32,533   81.2 (80.6-81.8)   46,567   64.8 (64.1-65.5)
  Local        2006-2010   877      95\. 9(94.3-97.1)   3,349      97.4 (96.7-98.0)   8,334    97.4 (96.9-97.9)   10,957   96.3 (95.6-96.9)   10,217   82.7 (81.6-83.9)
               2011-2015   804      96.8 (94.6-98.2)    3,370      97.1 (96.2-97.9)   10,729   97.9 (97.4-98.4)   12,767   97.6 (96.9-98.2)   14,472   88.6 (87.4-89.8)
  Regional     2006-2010   1,384    80.4 (78.2-82.4)    4,446      84.2 (83.0-85.2)   9,510    84.3 (83.5-85.1)   12,730   81.7 (80.9-82.5)   13,548   69.8 (68.7-70.8)
               2011-2015   1,341    85.6 (82.8-88.0)    4,416      86.8 (85.3-88.1)   11,639   87.2 (86.3-88.1)   13,838   85.9 (84.9-86.7)   20,667   73.8 (72.6-74.9)
  Distant      2006-1010   626      24.2 (20.9-27.7)    1,801      24.5 (22.5-26.6)   3,356    24.7 (23.2-26.2)   4,362    21.9 (20.6-23.2)   5,412    12.5 (11.5-13.5)
               2011-2015   592      21.1 (16.7-25.9)    1,884      28.0 (25.2-30.8)   4,102    25.8 (23.9-27.7)   4,633    23.0 (21.3-24.6)   7,732    11.8 (10.7-12.9)
  Unknown      2006-2010   274      81.1 (75.9-85.3)    875        75.6 (72.5-78.4)   1,913    78.9 (76.9-80.8)   2,836    72.4 (70.5-74.2)   4,772    42.4 (40.7-44.1)
               2011-2015   111      79.1 (68.3-86.6)    367        82.1 (76.8-86.4)   1,004    79.2 (75.9-82.1)   1,295    75.8 (72.7-78.7)   3,696    33.6 (31.3-35.9)

SEER, Surveillance, Epidemiology, and End Results; CI, confidence interval.

###### 

Five-year relative survival of all patients by age group and tumor distribution between 2006--2010 and 2011--2015

  Tumor distribution              Year        ≤39 yr   40-49 yr           50-59 yr   60-69 yr           ≥70 yr                                                           
  ------------------------------- ----------- -------- ------------------ ---------- ------------------ -------- ------------------ -------- ------------------ -------- ------------------
  Right side colon (C18.0-18.3)   2006-2010   626      78.5 (75.1-81.6)   1,519      78.7 (76.5-80.7)   3,363    76.9 (75.3-78.3)   5,256    74.9 (73.6-76.2)   6,559    62.0 (60.5-63.5)
                                  2011-2015   504      79.6 (74.8-83.5)   1,493      78.8 (76.0-81.3)   4,231    80.5 (79.0-82.0)   5,864    79.3 (77.9-80.7)   10,572   64.9 (63.4-66.4)
  Transverse colon (C18.4))       2006-2010   180      69.8 (62.5-76.0)   436        76.3 (71.9-80.1)   903      79.7 (76.8-82.4)   1,297    78.2 (75.5-80.7)   1,445    58.1 (54.8-61.3)
                                  2011-2015   174      78.5 (71.1-84.2)   394        78.1 (72.7-82.7)   1,038    83.3 (80.2-86.1)   1,504    80.0 (77.1-82.6)   2,395    66.1 (62.9-69.2)
  Left side colon (C18.5-18.7)    2006-2010   940      70.1 (67.1-73.0)   3,162      78.4 (76.9-79.9)   7,066    81.8 (80.9-82.8)   9,295    80.1 (79.2-81.1)   9,024    66.3 (64.9-67.6)
                                  2011-2015   851      74.5 (70.6-77.9)   3,137      81.0 (79.2-82.7)   8,839    83.8 (82.8-84.8)   10,345   83.9 (82.9-84.9)   12,983   69.1 (67.7-70.5)
  Rectosigmoid (C19.9)            2006-1010   175      72.4 (65.0-78.4)   698        76.8 (73.4-79.9)   1,683    80.1 (77.9-82.0)   2,234    80.0 (78.0-81.9)   2,352    63.9 (61.3-66.4)
                                  2011-2015   240      70.5 (62.0-77.4)   895        77.7 (73.9-81.1)   2,623    80.2 (78.0-82.2)   3,155    79.0 (76.8-81.0)   3,993    68.2 (65.7-70.7)
  Rectum (C20.9)                  2006-2010   1,068    74.2 (71.5-76.8)   4,108      76.6 (75.2-77.9)   8,796    79.7 (78.8-80.6)   10,972   76.9 (76.0-77.8)   11,804   59.8 (58.7-61.0)
                                  2011-2015   947      74.6 (70.7-78.1)   3,684      78.4 (76.6-80.1)   9,498    81.8 (80.7-82.8)   10,092   80.6 (79.5-81.7)   13,809   63.4 (62.0-64.7)

SEER, Surveillance, Epidemiology, and End Results; CI, confidence interval.
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